Eli Lilly is partnering with MeiraGTx to develop and commercialize ophthalmology gene therapies, and with SanegeneBio to ...

Markets have turned upbeat amid optimism that the 39-day US shutdown could soon come to an end, after a weekend of dealmaking in Washington. A new bill quickly advanced in a key S ...

The prolonged shutdown has taken a toll on consumer confidence and the overall economy, with consumer sentiment dropping to ...

MeiraGTx’s AAV-AIPL1 has already led to vision gains in blind children, as regulatory submissions for the gene therapy close ...

MeiraGTx will receive an upfront payment of $75 million and will be eligible to receive over $400 million in total milestone ...

The drugmaker is paying MeiraGTx $75 million upfront and $400 million in milestone payments to gain access to a treatment for LCA4 caused by AIPL1 mutations.

US clinical-stage genetic medicines company MeiraGTx Holdings saw its shares rise 15% to $9.74 pre-market today, as it ...

The alliance extends a deal streak in genetic medicine for Lilly and hands the company rights to an experimental treatment ...

MeiraGTx Holdings shares rose sharply in premarket trading Monday after the clinical-stage genetic-medicines said it formed a ophthalmology collaboration potentially worth hundreds of millions of ...

MeiraGTx Holdings has signed a deal with Eli Lilly , potentially worth over $475 million, granting the pharma giant rights to ...

MeiraGTx shares rise after signing a $475 million deal with Eli Lilly for a gene therapy program restoring vision in children ...

The latest announcement is out from Meiragtx Holdings ( (MGTX) ).